These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

588 related items for PubMed ID: 20854178

  • 1. PPARs as therapeutic targets in cardiovascular disease.
    van Bilsen M, van Nieuwenhoven FA.
    Expert Opin Ther Targets; 2010 Oct; 14(10):1029-45. PubMed ID: 20854178
    [Abstract] [Full Text] [Related]

  • 2. PPAR agonists: multimodal drugs for the treatment of type-2 diabetes.
    Gross B, Staels B.
    Best Pract Res Clin Endocrinol Metab; 2007 Dec; 21(4):687-710. PubMed ID: 18054742
    [Abstract] [Full Text] [Related]

  • 3. Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications.
    Touyz RM, Schiffrin EL.
    Vascul Pharmacol; 2006 Jul; 45(1):19-28. PubMed ID: 16782410
    [Abstract] [Full Text] [Related]

  • 4. Peroxisome proliferator-activated receptors and inflammation: take it to heart.
    Smeets PJ, Planavila A, van der Vusse GJ, van Bilsen M.
    Acta Physiol (Oxf); 2007 Nov; 191(3):171-88. PubMed ID: 17935522
    [Abstract] [Full Text] [Related]

  • 5. PPAR dual agonists: are they opening Pandora's Box?
    Balakumar P, Rose M, Ganti SS, Krishan P, Singh M.
    Pharmacol Res; 2007 Aug; 56(2):91-8. PubMed ID: 17428674
    [Abstract] [Full Text] [Related]

  • 6. Peroxisome proliferator-activated receptor alpha, delta, gamma1 and gamma2 expressions are present in human monocyte-derived dendritic cells and modulate dendritic cell maturation by addition of subtype-specific ligands.
    Jakobsen MA, Petersen RK, Kristiansen K, Lange M, Lillevang ST.
    Scand J Immunol; 2006 May; 63(5):330-7. PubMed ID: 16640656
    [Abstract] [Full Text] [Related]

  • 7. Phospholipase A2-modified low-density lipoprotein activates macrophage peroxisome proliferator-activated receptors.
    Namgaladze D, Morbitzer D, von Knethen A, Brüne B.
    Arterioscler Thromb Vasc Biol; 2010 Feb; 30(2):313-20. PubMed ID: 19948841
    [Abstract] [Full Text] [Related]

  • 8. Obesity, peroxisome proliferator-activated receptor, and atherosclerosis in type 2 diabetes.
    Blaschke F, Takata Y, Caglayan E, Law RE, Hsueh WA.
    Arterioscler Thromb Vasc Biol; 2006 Jan; 26(1):28-40. PubMed ID: 16239592
    [Abstract] [Full Text] [Related]

  • 9. [PPARs: physiological functions and pharmacological roles of agonists in human diseases. Note II].
    Filip-Ciubotaru F, Manciuc C, Grigore C, Foia L.
    Rev Med Chir Soc Med Nat Iasi; 2012 Jan; 116(1):240-7. PubMed ID: 23077903
    [Abstract] [Full Text] [Related]

  • 10. Healing the diabetic heart: modulation of cardiometabolic syndrome through peroxisome proliferator activated receptors (PPARs).
    Huang TH, Roufogalis BD.
    Curr Mol Pharmacol; 2012 Jun; 5(2):241-7. PubMed ID: 22122453
    [Abstract] [Full Text] [Related]

  • 11. PPAR ligands: are they potential agents for cardiovascular disorders?
    Balakumar P, Rose M, Singh M.
    Pharmacology; 2007 Jun; 80(1):1-10. PubMed ID: 17496434
    [Abstract] [Full Text] [Related]

  • 12. Differential responses of PPARalpha, PPARdelta, and PPARgamma reporter cell lines to selective PPAR synthetic ligands.
    Seimandi M, Lemaire G, Pillon A, Perrin A, Carlavan I, Voegel JJ, Vignon F, Nicolas JC, Balaguer P.
    Anal Biochem; 2005 Sep 01; 344(1):8-15. PubMed ID: 16038868
    [Abstract] [Full Text] [Related]

  • 13. Drug Insight: mechanisms of action and therapeutic applications for agonists of peroxisome proliferator-activated receptors.
    Gervois P, Fruchart JC, Staels B.
    Nat Clin Pract Endocrinol Metab; 2007 Feb 01; 3(2):145-56. PubMed ID: 17237841
    [Abstract] [Full Text] [Related]

  • 14. PPARs and their metabolic modulation: new mechanisms for transcriptional regulation?
    Ahmed W, Ziouzenkova O, Brown J, Devchand P, Francis S, Kadakia M, Kanda T, Orasanu G, Sharlach M, Zandbergen F, Plutzky J.
    J Intern Med; 2007 Aug 01; 262(2):184-98. PubMed ID: 17645586
    [Abstract] [Full Text] [Related]

  • 15. Inflammation in diabetes mellitus: role of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma agonists.
    Libby P, Plutzky J.
    Am J Cardiol; 2007 Feb 19; 99(4A):27B-40B. PubMed ID: 17307056
    [Abstract] [Full Text] [Related]

  • 16. [Nuclear receptors PPAR as a drug target in metabolic disorders].
    Stolarczyk M, Gutman W, Derlacz RA.
    Postepy Biochem; 2011 Feb 19; 57(2):207-14. PubMed ID: 21913422
    [Abstract] [Full Text] [Related]

  • 17. Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets.
    Brown JD, Plutzky J.
    Circulation; 2007 Jan 30; 115(4):518-33. PubMed ID: 17261671
    [Abstract] [Full Text] [Related]

  • 18. Peroxisome proliferator-activated receptors (PPARs) in the control of bone metabolism.
    Giaginis C, Tsantili-Kakoulidou A, Theocharis S.
    Fundam Clin Pharmacol; 2007 Jun 30; 21(3):231-44. PubMed ID: 17521292
    [Abstract] [Full Text] [Related]

  • 19. Dual PPAR alpha/gamma agonists: promises and pitfalls in type 2 diabetes.
    Ahmed I, Furlong K, Flood J, Treat VP, Goldstein BJ.
    Am J Ther; 2007 Jun 30; 14(1):49-62. PubMed ID: 17303976
    [Abstract] [Full Text] [Related]

  • 20. Peroxisome proliferator-activated receptor (PPAR)-gamma positively controls and PPARalpha negatively controls cyclooxygenase-2 expression in rat brain astrocytes through a convergence on PPARbeta/delta via mutual control of PPAR expression levels.
    Aleshin S, Grabeklis S, Hanck T, Sergeeva M, Reiser G.
    Mol Pharmacol; 2009 Aug 30; 76(2):414-24. PubMed ID: 19483106
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.